MultiVu Video Feed: FDA Approves Viread(R) For Chronic Hepatitis B

Tuesday, August 12, 2008 General News J E 4
NEWS: New treatment option approved for life-threatening liver diseasefor which medicines are urgently needed. The complications of chronichepatitis B kill 1 in 4 of those affected.

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, hard copy requests, downloadable MPEG2,contact information and more available at

STORY SUMMARY: The FDA has approved Viread(R) (tenofovir disoproxilfumarate) as a treatment option for adults with chronic hepatitis B, a seriousliver disease. Chronic hepatitis B affects an estimated 2 million people inthe United States and is the leading cause of liver cancer worldwide.

Caused by the hepatitis B virus (HBV), a pathogen that is up to 100 timesmore infectious than the AIDS virus, chronic hepatitis B disproportionatelyaffects Asian Americans, who represent nearly half of all cases and are one ofthe fastest-growing population groups in the country.

Because chronic HBV infection can persist for years without causingnoticeable symptoms, the disease is known as a "silent killer" and many peopleare unaware they are infected. New treatment options are urgently needed -- 1in 4 people with the disease ultimately die from serious complications such aschronic liver disease, cirrhosis or liver cancer.

Viread is taken as a once-daily tablet, and works by blocking the enzymethat is necessary for the hepatitis B virus to replicate in liver cells.Viread has been available in the United States as a part of combinationtherapy for HIV infection since 2001, and its active ingredient is themost-prescribed compound in HIV therapy.

To learn more about VIREAD, including box warnings, important safetyinformation and full prescribing information, please visit


-- Fred Poordad, MD / Chief of Hepatology, Cedars-Sinai Center for LiverDisease and Transplantation, Los Angeles

-- Danny Chu, MD / Community Physician, Chinatown, New York City

-- Fiona Ma / Hepatitis B patient, California Assemblywoman, San Francisco

B-ROLL INCLUDES: Viread packaging and manufacturing** Doctor/patient**Gilead campus**Leading Cause of Liver Cancer Affects 2 Million People in United States SATELLITE FEEDS: Monday, August 11th, 2008 Tuesday, August 12th, 2008 7:30 PM - 7:45 PM ET 3:00 AM - 3:15 AM ET Galaxy 28 Galaxy 28 Transponder 15 Transponder 15 C-Band C-Band Downlink Freq: 4000 Vertical Downlink Freq: 4000 Vertical Tuesday, August 12th, 2008 1:00 PM - 1:15 PM ET AMC 3 Transponder 19 C-Band Downlink Freq: 4080 Horizontal

SOURCE Gilead Sciences


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Bronchitol Cystic Fibrosis Dose Trial Results Posi...
KV Pharmaceutical Company Reports Fiscal 2009 Firs...